Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS

NCT04119440 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

145

Enrollment

OTHER

Sponsor class

Conditions

MERS (Middle East Respiratory Syndrome)

Interventions

BIOLOGICAL: MVA-MERS-S_DF1 - Low Dose
BIOLOGICAL: MVA-MERS-S_DF1 - High Dose
OTHER: Placebo

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]